At a glance
ClinicalIndex Comparison RecordN/ACompleted· 66 enrolled
Drug / intervention
Lanthanum carbonatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IV, Multi-Centre, Non-interventional Study Evaluating the Effect of Lanthanum Carbonate in Patients Previously Treated With Calcium Based Phosphate Binder Therapy on Serum Phosphorous Control, Concomitant Vitamin D Therapy and Bone Related Biochemical Parameters in End Stage Renal Disease Patients on Hemodialysis
In Brief
An observational study evaluating Lanthanum carbonate for End Stage Renal Disease. Completed, enrolled 66 participants across 31 sites.
Detailed Summary
To assess the percentage of patients on lanthanum carbonate, that achieve Kidney Disease Outcome Quality Initiative (KDOQI) guideline suggested values for serum phosphorous in patients previously treated with calcium-based phosphate binder therapy.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsEnd Stage Renal Disease
CountriesGermany
Collaborators--
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2010
First PostedMay 2010
Primary CompletionJun 2012
TodayJul 2026
First PostedMay 26, 2010
Enrollment StartApr 26, 2010
Primary CompletionJun 12, 2012
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 16.1 years ago
Interventions
Lanthanum carbonatedrug